Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis |
| |
| Institution: | 1. Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria;2. Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria;3. Private University of the Principality of Liechtenstein, Triesen, Liechtenstein;4. Drexel University College of Medicine, Philadelphia, PA, USA;1. Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui 230032, China;2. The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, Anhui 230032, China;3. Department of Rheumatism and Immunity, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230032, China;1. 3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminen hospital, Vienna, Austria;2. Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden;3. Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria;4. Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria;5. Sigmund Freud University, Medical Faculty, Vienna, Austria;6. Core Facilities, Medical University of Vienna, Vienna, Austria;1. Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China;2. Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China |
| |
| Abstract: | BackgroundDyslipidemia in rheumatoid arthritis (RA) patients is frequently observed, and treatment with anti-rheumatic drugs has an impact on lipid profiles. Pathophysiologically, inflammation leads to decreased blood lipids and lipoproteins; RA treatment reduces inflammation and therefore may increase lipids and lipoproteins. Whether the lipid changes with RA treatment confer an increased risk of cardiovascular disease or just reflect their potentially atheroprotective anti-inflammatory effect is currently unclear due to limited and conflicting data.ObjectiveThe aim of this review is to summarize the current knowledge on the effects of synthetic and biological disease modifying antirheumatic drugs for the treatment of RA on lipid and lipoprotein parameters.ResultsRecent studies on methotrexate emphasize its anti-atherogenic effect. Golimumab combined with methotrexate revealed a trend towards an anti-atherogenic potential. The known pro-atherogenic lipid-spectrum alterations caused by tofacitinib can be effectively treated with atorvastatin. Tocilizumab signals a favorable impact on the extent of lipid modifications when combined with methotrexate. Abatacept indicated a trend towards an anti-atherogenic lipid profile demonstrated by favorable effects on HDL-C and on the TC/HDL-C ratio. Rituximab has beneficial effects on HDL-C and ApoA1, as well as on the ApoB/ApoA1 ratio.Clinical implicationsAnti-rheumatic drugs have various effects on lipid parameters, which in part appear pro-atherogenic. However, because many of these lipid changes may well reflect their potentially atheroprotective anti-inflammatory action the cardiovascular impact of these changes remains unclear. Whatsoever, cardiovascular safety trials for antirheumatic drugs would be valuable. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
